# Safety And Efficacy Of Lenalidomide In Patients With Relapsed Or Refractory Aggressive Non-Hodgkin's Lymphoma (NHL)

> **NCT00179660** · PHASE2 · COMPLETED · sponsor: **Celgene Corporation** · enrollment: 50 (actual)

## Conditions studied

- Non-Hodgkins Lymphoma

## Interventions

- **DRUG:** Lenalidomide

## Key facts

- **NCT ID:** NCT00179660
- **Lead sponsor:** Celgene Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-08
- **Primary completion:** 2008-06
- **Final completion:** 2008-06
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2016-01-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00179660

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00179660, "Safety And Efficacy Of Lenalidomide In Patients With Relapsed Or Refractory Aggressive Non-Hodgkin's Lymphoma (NHL)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00179660. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*